Combination of Electroporation Delivered Metabolic Modulators with Low-dose Chemotherapy in Osteosarcoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Aug 25

PMID 30140384

Citations 1

Authors

Kheshwant S Gill

Philana Fernandes

Brian Bird

Declan M Soden

Patrick F Forde

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcoma accounts for roughly 60% of all malignant bone tumors in children and young adults. The five-year survival rate for localized tumors after surgery and chemotherapy is approximately 70% whilst it drastically reduces to 15-30% in metastatic cases. Metabolic modulation is known to increase sensitivity of cancers to chemotherapy. A novel treatment strategy in Osteosarcoma is needed to battle this devastating malady.

Results: Electroporation-delivered metabolic modulators were more effective in halting the cell cycle of Osteosarcoma cells and this negatively affects their ability to recover and proliferate, as shown in colony formation assays. Electroporation-delivered metabolic modulators increase the sensitivity of Osteosarcoma cells to chemotherapy and this combination reduces their survivability.

Conclusion: This novel treatment approach highlights the efficacy of electroporation in the delivery of metabolic modulators in Osteosarcoma cells, and increased sensitivity to chemotherapy allowing for a lower dose to be therapeutic.

Methods: Metabolic modulations of two Osteosarcoma cell lines were performed with clinically available modulators delivered using electroporation, and its combination with low-dose Cisplatin. The effects of Dicholoroacetic acid, 2-Deoxy-D-glucose and Metformin on cell cycle and recovery of Osteosarcoma cells were assessed. Their sensitivity to chemotherapy was also assessed when treated in combination with electroporation-delivered metabolic modulators.

Citing Articles

How physical techniques improve the transdermal permeation of therapeutics: A review.

Gao Y, Du L, Li Q, Li Q, Zhu L, Yang M Medicine (Baltimore). 2022; 101(26):e29314.

PMID: 35777055 PMC: 9239599. DOI: 10.1097/MD.0000000000029314.

References

Ward P, Thompson C . Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308. PMC: 3311998. DOI: 10.1016/j.ccr.2012.02.014. View

Lopez-Guerrero J, Lopez-Gines C, Pellin A, Carda C, Llombart-Bosch A . Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol. 2004; 13(2):81-91. DOI: 10.1097/00019606-200406000-00004. View

Ganapathy-Kanniappan S, Geschwind J . Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013; 12:152. PMC: 4223729. DOI: 10.1186/1476-4598-12-152. View

Hughes D . Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv. 2009; 6(12):1311-21. PMC: 4163784. DOI: 10.1517/17425240903280422. View

Biermann J, Chow W, Reed D, Lucas D, Adkins D, Agulnik M . NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(2):155-167. DOI: 10.6004/jnccn.2017.0017. View

Mir L, Belehradek M, Domenge C, Orlowski S, Poddevin B, BELEHRADEK Jr J . [Electrochemotherapy, a new antitumor treatment: first clinical trial]. C R Acad Sci III. 1991; 313(13):613-8. View

Smeland S, Wiebe T, Brosjo O, Bohling T, Alvegard T . Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl. 2004; 75(311):87-91. DOI: 10.1080/00016470410001708370. View

Marina N, Gebhardt M, Teot L, Gorlick R . Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9(4):422-41. DOI: 10.1634/theoncologist.9-4-422. View

Chou A, Gorlick R . Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006; 6(7):1075-85. DOI: 10.1586/14737140.6.7.1075. View

10.

Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K . Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate. 2010; 70(13):1388-94. PMC: 4142700. DOI: 10.1002/pros.21172. View

11.

Nyberg K, Michelson R, Putnam C, Weinert T . Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet. 2002; 36:617-56. DOI: 10.1146/annurev.genet.36.060402.113540. View

12.

Orlowski S, BELEHRADEK Jr J, Paoletti C, Mir L . Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol. 1988; 37(24):4727-33. DOI: 10.1016/0006-2952(88)90344-9. View

13.

Blay J . Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle. Onkologie. 2007; 30(5):226-7. DOI: 10.1159/000101702. View

14.

Harris J, Chen A, Macias V, Mahon B, Chiu B, Pillai S . Irreversible Electroporation as an Effective Technique for Ablating Human Metastatic Osteosarcoma. J Pediatr Hematol Oncol. 2016; 38(3):182-6. DOI: 10.1097/MPH.0000000000000516. View

15.

Munoz-Pinedo C, El Mjiyad N, Ricci J . Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012; 3:e248. PMC: 3270265. DOI: 10.1038/cddis.2011.123. View

16.

Raez L, Papadopoulos K, Ricart A, Chiorean E, DiPaola R, Stein M . A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; 71(2):523-30. DOI: 10.1007/s00280-012-2045-1. View

17.

DeLaney T, Park L, Goldberg S, Hug E, Liebsch N, Munzenrider J . Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005; 61(2):492-8. DOI: 10.1016/j.ijrobp.2004.05.051. View

18.

Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J . Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 2011; 72(1):304-14. PMC: 3601736. DOI: 10.1158/0008-5472.CAN-11-1674. View

19.

Li X, Xu K, Li W, Qiu X, Ma B, Fan Q . Immunologic response to tumor ablation with irreversible electroporation. PLoS One. 2012; 7(11):e48749. PMC: 3490901. DOI: 10.1371/journal.pone.0048749. View

20.

Machak G, Tkachev S, Solovyev Y, Sinyukov P, Ivanov S, Kochergina N . Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. 2003; 78(2):147-55. DOI: 10.4065/78.2.147. View